Immix Biopharma (IMMX) Receivables - Net (2024 - 2026)

Quarterly results put Receivables - Net at $6.2 million for Q1 2026, up 264.71% from a year ago — trailing twelve months through Mar 2026 was $6.2 million (up 264.71% YoY), and the annual figure for FY2025 was $4.6 million, up 142.11%.

Immix Biopharma has reported Receivables - Net over the past 3 years, most recently at $6.2 million for Q1 2026.

  • Receivables - Net reached $6.2 million in Q1 2026 per IMMX's latest filing, up from $4.6 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $6.2 million in Q1 2026 and bottomed at $1.7 million in Q1 2025.
  • Median Receivables - Net over the past 3 years was $4.1 million (2025), compared with a mean of $3.8 million.
  • The largest annual shift saw Receivables - Net soared 142.11% in 2025 before it skyrocketed 264.71% in 2026.
  • Over 3 years, Receivables - Net stood at $1.9 million in 2024, then skyrocketed by 142.11% to $4.6 million in 2025, then soared by 34.78% to $6.2 million in 2026.
  • Business Quant data shows Receivables - Net for IMMX at $6.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn -
5 Akari Therapeutics 605.66 Bn 605.66 Bn -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn
8 Evaxion A 65.12 Bn 65.10 Bn -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn
10 Immix Biopharma 476.17 Mn 476.17 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 6.20 Mn
Mar 31, 2026 6.20 Mn
Dec 31, 2025 4.60 Mn
Dec 31, 2025 4.60 Mn
Sep 30, 2025 4.60 Mn
Sep 30, 2025 4.60 Mn
Jun 30, 2025 3.60 Mn
Jun 30, 2025 3.60 Mn
Mar 31, 2025 1.70 Mn
Mar 31, 2025 1.70 Mn
Dec 31, 2024 1.90 Mn
Dec 31, 2024 1.90 Mn